Cowen & Co. Sticks to Their Hold Rating for Zafgen (ZFGN)

By Austin Angelo

In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Zafgen (ZFGNResearch Report). The company’s shares opened today at $4.98, close to its 52-week low of $4.51.

According to, Nadeau is a 4-star analyst with an average return of 5.6% and a 47.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Zafgen.

See today’s analyst top recommended stocks >>

Based on Zafgen’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $15.07 million. In comparison, last year the company had a GAAP net loss of $13.09 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which is engages in the development of therapeutics for both rare and prevalent metabolic diseases including type 2 diabetes, Prader-Willi syndrome, or PWS, and potentially other metabolically related disorders.